Nirmatrelvir-ritonavir (Paxlovid) continues to provide a benefit, especially in the elderly and less vaccinated

Clinical Question

In the omicron phase of the COVID-19 pandemic in a mostly vaccinated population, is nirmatrelvir-ritonavir still effective at reducing hospitalizations and death in outpatients?

Bottom line

In this well-done propensity score matched study, Paxlovid continues to provide a clinically meaningful reduction in hospitalizations and mortality, especially for the less vaccinated and for adults older than 70 years. This is the third methodologically sound study to come to this conclusion. In the absence of randomized trials, this represents our best available evidence. 2c

Study design: Case-control

Funding: Government

Setting: Outpatient (any)

Reviewer

Mark H. Ebell, MD, MS
Professor
University of Georgia
Athens, GA


Discuss this POEM


Comments

Arup Kumar Dhara

Impact assessment

Excellent

Kathleen Alayna Clarkson

Words matter

Great review. Wish we could get away from using the term "elderly" in these summaries - a largely outdated term with negative/ageist connotations

Anonymous

Paxlovid still of benefit

I took Paxlovid myself when I had covid. Hard on there stomach, but it sure helped the worsening chest congestion